You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing
SBC: TREVIGEN, INC. Topic: 113DESCRIPTION provided by applicant The objective of this Phase STTR research is to quantify genotoxicity in basal cell keratinocytes from organotypic cultures Epiderm in response to commonly used chemical agents The proposed product is a Comet Chip assay that measures DNA damage in basal cells derived from a reconstructed human epidermis Technical questions that will be addressed are Ca ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma
SBC: Cyteir Therapeutics, Inc. Topic: NCIDESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
"Extra Innings”: Using Serious Gaming and the Science of Baseball to Teach Science and Mathematics
SBC: DFUSION INC. Topic: 999DESCRIPTION provided by applicant Due to the rapid advances in science technology engineering and mathematics STEM the United States has been at the forefront of innovation and technology development in the science health and biomedical fields However these continuing advances are in jeopardy as there is a growing national shortage of trained STEM workers While the need for a STEM li ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Small, high-affinity ligands for array tomography
SBC: ARATOME, LLC Topic: 101DESCRIPTION provided by applicant Neurodegenerative diseases are among the most expensive disruptive and least well treated of human maladies arguably because they are not well understood Array tomography AT is a method for tissue imaging with resolution in all three dimensions sufficient to resolve individual synapses and provide quantitative characterization ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Skin Sympathetic Nerve Activity and Cardiac Arrhythmias
SBC: ARRHYTHMOTECH Topic: NIDADESCRIPTION provided by applicant The objective of this Phase II STTR grant application is to continue the R Randamp D efforts initiated in Phase I The long term objective for Arrhythmotech is to develop and market an instrument for the simultaneous recording of sympathetic nerve activity SNA and electrocardiogram ECG using electrodes on the skin This method neuECG was discovered in Dr ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors
SBC: NEONC TECHNOLOGIES INC Topic: BTDESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of Optimized Endectocide-treated Bird Feed Formulations for West Nile Virus Control
SBC: TDA RESEARCH, INC. Topic: NIAIDProject Summary Abstract Development of Optimized Endectocide treated Bird Feed Formulations for West Nile Virus Control STTR Phase I Application PIs Brady Clapsaddle TDA Research Inc Dr Brian Foy Colorado State University West Nile Virus WNV is the leading cause of domestically acquired arboviral disease in the United States resulting in significant disease and death every year in both ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDDESCRIPTION provided by applicant The ebolaviruses and Marburg virus MARV constitute the family Filoviridae andquot filovirusesandquot that cause severe hemorrhagic fever with human case fatalities of The current epidemic in West Africa unprecedented in terms of geographic scope and size highlights the continued need for development of therapeutics Among the five ebolavirus spe ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A universal vaccine for the prevention of meningococcal meningitis in Africa
SBC: OMVAX INC Topic: RFor more than years sub Saharan Africa has suffered with high rates of endemic meningococcal disease and periodic epidemic epidemics involving over cases In a low cost serogroup A polysaccharide protein conjugate vaccine MenAfriVac was introduced in the region The vaccine confers protection against serogroup A MenA disease as well as asymptomatic nasopharyngeal MenA carria ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health